PT  - JOURNAL ARTICLE
AU  - Lim, Lew
AU  - Hosseinkhah, Nazanin
AU  - Buskirk, Mark V.
AU  - Berk, Andrea
AU  - Loheswaran, Genane
AU  - Abbaspour, Zara
AU  - Karimpoor, Mahta
AU  - Smith, Alison
AU  - Au, Yoke N.
AU  - Ho, Kai F
AU  - Pushparaj, Abhiram
AU  - Zahavi, Michael
AU  - White, Alexander
AU  - Rubine, Jonathan
AU  - Zidel, Brian
AU  - Henderson, Christopher
AU  - Clayton, Russell G.
AU  - Tingley, David R.
AU  - Miller, David J.
AU  - Karimpoor, Mahroo
AU  - Hamblin, Michael R.
TI  - Home-use Photobiomodulation Device Treatment Outcomes for COVID-19
AID  - 10.1101/2022.06.16.22276503
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.16.22276503
4099  - http://medrxiv.org/content/early/2022/06/17/2022.06.16.22276503.short
4100  - http://medrxiv.org/content/early/2022/06/17/2022.06.16.22276503.full
AB  - BACKGROUND There is need for non-pharmaceutical treatments for COVID-19. A home-use photobiomodulation (PBM) device was tested as Treatment in a randomized clinical trial.METHODS 294 patients were randomized with equal allocation to Treatment or Standard of Care (Control). 199 qualified for efficacy analyses. The Treatment group self-treated for 20 minutes twice daily, for the first 5 days, and subsequently once daily for 30 days. A validated respiratory questionnaire was used, and patients were monitored remotely. The primary endpoint was the time-to-recovery (3 consecutive days of no sickness) for general sickness. The Kaplan-Meier method and the Cox Proportional Hazards model were primary methods of analyses.RESULTS Treatment patients with collective 0-12 days of symptoms, at moderate-to-severe level on Day 1 of Treatment, did not recover significantly faster than Control. However, for patients with 0-7 days of symptoms there was a significant mean difference of 3 days: Treatment, 18 days (95% CI, 13-20) vs. Control, 21 days (95% CI, 15-28), P=0.050. The Treatment:Control hazard ratio at 1.495 (95% CI, 0.996-2.243), P=0.054 exceeded the pre-trial target of 1.44. Treated patients exceeding 7 days symptoms duration were more tired and had lower energy. None of the patients in the Treatment group suffered death or hospitalization while the Control group had 1 death and 3 severe adverse events requiring hospitalization.CONCLUSIONS Patients with up to 7 days of symptoms at moderate-to-severe levels on first day of Treatment can expect faster recovery for general sickness and several respiratory symptoms. (Funded by Vielight Inc.; ClinicalTrials.gov number, NCT04418505.)Competing Interest StatementLew Lim: Employee of sponsor, Vielight Inc., Nazanin Hosseinkhah: Employee of sponsor, Vielight Inc., Mark Van Buskirk: Paid consultant for the study, Andrea Berk: Paid consultant for the study, Genane Loheswaran: Employee of sponsor, Vielight Inc., Zara Loheswaran: Employee of sponsor, Vielight Inc., Alison Smith: Ex-employee of sponsor, Vielight Inc., was a co-investigator in the study, Mahta Karimpoor: Ex-employee of sponsor, Vielight Inc., was a co-investigator in the study, Yoke N Au: Employee of sponsor, Vielight Inc., Kai F Ho: Paid consultant for the study, Abhiram Pushparaj: Paid consultant for the study, Michael Zahavi: Paid investigator for the study, Alexander White: Paid investigator for the study, Jonathan Rubine: Paid investigator for the study, Brian Zidel: Paid investigator for the study, Christopher Henderson: Paid consultant for the study, Russell G Clayton Sr: Paid investigator for the study, David R Tingley: Paid investigator for the study, David J Miller: Paid investigator for the study, Mahroo Karimpoor: Employee of sponsor, Vielight Inc., Michael R Hamblin: Paid advisor to sponsor, Vielight Inc. Clinical TrialNCT04418505Funding StatementThis study was funded by Vielight Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval granted by IRB: Advarra, Inc., and its affiliated entities, with a principal place of business at 6940 Columbia Gateway Drive, Suite 110, Columbia, MD 21046.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.